The four-pronged strategy begins with the acquisition of GSK's oncology portfolio, which includes all of its marketed products and late-stage candidates, for $14.5 billion, with a further $1.5 ...

Most of this spent is out of the pocket. By providing a big portfolio of 140 products with a relative low price, GSK is winning the game of "volume" in the market. This large portfolio also gives ...

We recently published a list of the 7 Most Undervalued Biotech Stocks To Invest In. In this article, we are going to take a ...

GSK said on Tuesday that it is studying a group of more than a million older adults in the UK to examine whether its ...

Bringing people together is the best way to innovate and deliver products that transform ... the vaccines of the future. GSK’s broad and far-reaching vaccine portfolio. GSK’s marketed vaccines ...

“Emma led the executive team and the wider organisation to deliver continued, improved operating performance in 2024, with GSK’s reshaped product portfolio demonstrating both strength and ...

The company’s oncology portfolio, which had been facing ... or under regulatory review. This year, GSK expects to launch five new products/line extensions, including Blenrep (relaunch in ...

In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other best vaccine stocks to buy now. On February 24, CNBC reported that President Trump declared that ...

("GSK" or the "Company") (NYSE ... Provide specific products and services to you, such as portfolio management or data aggregation. Develop and improve features of our offerings.